论文部分内容阅读
用放射示踪术研究了肾显像剂~(99m)Tc-PAHIDA摄入体内的代谢特性与临床诊断使用。观察表明,~(99m)Tc-PAHIDA在体内呈优势定位于肾脏,而在其后依次为心脏、胃肠道、肝、脾、股四头肌、脂肪、睾丸和脑组织。尤其值得指出的是,当该肾显像剂的摄入量愈低时,则其在肾脏的选择性浓集程度就愈高。同时其与血浆蛋白的结合程度就愈低。~(99m)Tc-PAHIDA可迅速经肾脏排出体外,而且由尿色层分析放射自显影观察得到一个放射峰,从而证明~(99m)Tc-PAHIDA在体内是以原形经尿排除的。
The metabolic characteristics and clinical diagnosis of renal imaging agent ~ (99m) Tc-PAHIDA in vivo were studied by radiotracer. The observation showed that ~ (99m) Tc-PAHIDA predominantly localized to the kidney in the body, followed by heart, GI tract, liver, spleen, quadriceps, fat, testes and brain tissue. In particular, it is worth pointing out that when the intake of the kidney imaging agent is lower, its selective concentration in the kidney is higher. At the same time the lower the degree of its binding to plasma proteins. ~ (99m) Tc-PAHIDA can be rapidly excreted through the kidneys, and a radioactive peak was observed by urinalysis autoradiography, demonstrating that ~ (99m) Tc-PAHIDA is excreted in vivo.